In our comparison between two neuroblastoma cell lines representatives of ALK-driven and MYCN-amplified disease, there is clearly heterogeneity of response to ASCL1 knockout despite similar initial expression levels. This evidence concerns the gene ASCL1 and neuroblastoma.